ATE142505T1 - Antikörper, spezifisch gegen elam-1 sowie deren verwendung - Google Patents

Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Info

Publication number
ATE142505T1
ATE142505T1 AT89912817T AT89912817T ATE142505T1 AT E142505 T1 ATE142505 T1 AT E142505T1 AT 89912817 T AT89912817 T AT 89912817T AT 89912817 T AT89912817 T AT 89912817T AT E142505 T1 ATE142505 T1 AT E142505T1
Authority
AT
Austria
Prior art keywords
elam
antibodies specific
expression
detecting
endothelialleukocyte
Prior art date
Application number
AT89912817T
Other languages
English (en)
Inventor
Michael P Bevilacqua
Michael A Gimbrone
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE142505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE142505T1 publication Critical patent/ATE142505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT89912817T 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung ATE142505T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27086088A 1988-11-14 1988-11-14

Publications (1)

Publication Number Publication Date
ATE142505T1 true ATE142505T1 (de) 1996-09-15

Family

ID=23033111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912817T ATE142505T1 (de) 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Country Status (8)

Country Link
US (1) US5403713A (de)
EP (1) EP0534944B1 (de)
JP (1) JPH04501565A (de)
AT (1) ATE142505T1 (de)
AU (1) AU636589B2 (de)
CA (1) CA2002860A1 (de)
DE (1) DE68927188T2 (de)
WO (1) WO1990005539A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0408859B1 (de) * 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Monoklonale Antikörper gegen aktivierte endotheliale Zellen
AU9055091A (en) * 1990-11-08 1992-06-11 Biogen, Inc. Treatment for inflammatory bowel disease
WO1992009293A1 (en) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
CA2100681A1 (en) * 1991-01-24 1992-07-25 Elisabeth Wayner Monoclonal antibodies to elam-1 and their uses
AU667813B2 (en) * 1991-05-03 1996-04-18 Rockefeller University, The Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions
US5629162A (en) * 1991-06-11 1997-05-13 The Center For Blood Research Method of identifying agents which modulate ICAM-3 binding to LFA-1
WO1993002702A1 (en) * 1991-07-31 1993-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
GB9120768D0 (en) * 1991-09-30 1991-11-13 British Bio Technology Diagnostic and prognastic materials and methods
HUT69725A (en) * 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
JP3616090B2 (ja) * 1992-01-27 2005-02-02 イコス コーポレイション 細胞間接着分子関連タンパク質
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
WO1995018379A1 (fr) * 1993-12-27 1995-07-06 The Nisshin Oil Mills, Ltd. Methode d'analyse d'un complexe forme entre la secretine et un ligand de celle-ci et utilisation dudit complexe
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6096511A (en) * 1997-06-10 2000-08-01 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
AU741017B2 (en) * 1997-06-10 2001-11-22 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EA200001007A1 (ru) 1998-03-31 2001-04-23 Дюпон Фармасьютикалз Компани Фармацевтические препараты для визуализации ангиогенных расстройств
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US20020160441A1 (en) * 1998-06-02 2002-10-31 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
EP4093508A1 (de) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin-antikörper, zusammensetzungen und verwendungsverfahren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1

Also Published As

Publication number Publication date
AU636589B2 (en) 1993-05-06
EP0534944A1 (de) 1993-04-07
DE68927188T2 (de) 1997-04-24
DE68927188D1 (de) 1996-10-17
AU4621789A (en) 1990-06-12
JPH04501565A (ja) 1992-03-19
US5403713A (en) 1995-04-04
EP0534944A4 (de) 1991-09-23
CA2002860A1 (en) 1990-05-14
WO1990005539A1 (en) 1990-05-31
EP0534944B1 (de) 1996-09-11

Similar Documents

Publication Publication Date Title
DE68927188D1 (de) Antikörper, spezifisch gegen elam-1 sowie deren verwendung
MX9203245A (es) Linea celular producida mediante una tecnica de hibridoma.
ES2182836T3 (es) Dispositivos de lectura para tiras de analisis.
ATE78697T1 (de) Kombination von angiotensin- converting-enzymehemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln.
AU6859696A (en) Efficient enrichment and detection of disseminated tumor cells
ES2037638T1 (es) Un metodo de generacion de luz.
DE3580927D1 (de) Die antigenischen determinanten von hbxag.
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
DE3584035D1 (de) Nachweis von menschlichem cytomegalovirus-spezifischem igm.
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
IT8548600A0 (it) Pellicole sottili di polietilene ad alto peso molecolare,e procedimento per la loro preparazione
ATE71149T1 (de) Monoklonale antikoerper.
ES2001013A6 (es) Un metodo para la preparacion de anticuerpos especificos de histamina
ES8702829A1 (es) Un tubo aplastable para suministrar un material pastoso.
DE3864645D1 (de) Langkettige n-alkyl-alpha-alkyl-nitrone sowie deren verwendung als stabilisatoren.
DE3670307D1 (de) Spezifische mycoplasma-membran-antigene und -antikoerper sowie deren klinische verwendungen.
FR2621127B1 (fr) Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
AU538833B2 (en) Method of diagnosing arterosclerosis
IT8619736A1 (it) Macchina atta ad effettuare, in modo automatico, la fascettatura di mazzette di banconote e simili, mediante nastro termosaldabile
JP2000171467A5 (de)
McCartney Development of instrumentation for use with the 10 S 3. 5 KHz acoustic transponders fitted into experimental penetrators.
BE904811A (fr) Anticorps monoclonaux.
DE3854740D1 (de) Menschlicher monoklonaler antikörper gegen candida.
Prast Tajikistan: Gold and Other Mining Prospects
ATE256737T1 (de) Rekombinantes cdw52 antigen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee